FDA to Review Confirmatory Data for Elahere in Platinum-Resi

The FDA has accepted for Priority Review the sBLA supporting the conversion to full approval of Elahere for platinum-resistant ovarian cancer.

Related Keywords

Michael Vasconcelles , Drug Administration , Priority Review , Biologics License Application , Executive Vice President , Prescription Drug User Fee Act ,